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The mammalian P2X7 receptors (P2X7Rs), a member of the ionotropic P2X receptor family
with distinctive functional properties, play an important part in mediating extracellular ATP
signaling in health and disease. A clear delineation of the molecular mechanisms underlying
the key receptor properties, such as ATP-binding, ion permeation, and large pore forma-
tion of the mammalian P2X7Rs, is still lacking, but such knowledge is crucial for a better
understanding of their physiological functions and contributions in diseases and for devel-
opment of therapeutics.The recent breakthroughs in determining the atomic structures of
the zebrafish P2X4.1R in the closed and ATP-bound open states have provided the long-
awaited structural information.The human P2RX7 gene is abundant with non-synonymous
single nucleotide polymorphisms (NS-SNPs), which generate a repertoire of human P2X7Rs
with point mutations. Characterizations of the NS-SNPs identified in patients of various dis-
ease conditions and the resulting mutations have informed previously unknown molecular
mechanisms determining the mammalian P2X7R functions and diseases. In this review,
we will discuss the new insights into such mechanisms provided by structural modeling
and recent functional and genetic linkage studies of NS-SNPs.
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INTRODUCTION
It has been well established that extracellular ATP is a widely used
signaling molecule in both excitable and non-excitable cells (Burn-
stock et al., 2010; Burnstock, 2012). As one key constituent mediat-
ing extracellular ATP signaling, mammalian cells express a family
of P2X proteins, P2X1–P2X7, which form homo/hetero-trimeric
ionotropic receptors at the cell surface exclusively responding to
extracellular ATP (North, 2002; Khakh and North, 2006). Many
studies over the past decade, and in particular those using trans-
genic mice, have gathered a large volume of evidence to show
pivotal roles for the mammalian P2XRs in a wide range of
physiological and pathological processes (Surprenant and North,
2009; Jiang, 2012; Kaczmarek-Hajek et al., 2012). The mammalian
P2XRs have been also subject to extensive site-directed mutagen-
esis studies, which, with the aid of the recently determined atomic
structures of the zebrafish P2X4.1R in the closed and ATP-bound
open states (Kawate et al., 2009; Hattori and Gouaux, 2012), have
significantly enriched our understanding of the molecular mech-
anisms that determine the common functional properties of the
mammalian P2XRs: ATP-binding, ion permeation, and channel
gating (Browne et al., 2010; Evans, 2010; Young, 2010; Khakh and
North, 2012; Jiang et al., 2013).
The P2X7 receptor (P2X7R) is unique among the P2XR family,
exhibiting distinctive or hallmark pharmacological and functional
properties (Jiang, 2009). The concentration of ATP required to
activate the P2X7R is one or two orders of magnitude greater than
for the other P2XRs. 2′-(3′)-O-(4-benzoylbenzoyl)-ATP (BzATP),
a synthetic ATP analog, is more potent at the P2X7R than ATP,
whereas the reverse order of potency is true at the other P2XRs
(North and Surprenant, 2000). The P2X7R confers cells with
an exceptionally dynamic permeability. Brief activation opens a
canonical ligand-gated ion channel selectively permeable to small
cations (Surprenant et al., 1996), and the P2X7R ion channel
displays remarkable facilitation or sensitization upon repetitive
agonist applications (Roger et al., 2008, 2010a; Yan et al., 2010).
It is the prototypic ionotropic receptor that induces formation of
a pore capable of passing much larger molecules in response to
prolonged or repetitive activation; formation of such a large pore
is often shown by influx and intracellular accumulation of extra-
cellular fluorescent dyes, such as YO-PRO-1 and ethidium, or a
progressive increase in membrane permeability to large organic
cations, such as N -methyl-d-glucamine (Surprenant et al., 1996;
Jiang et al., 2005). The mammalian P2X7Rs are highly expressed
in immune cells and also in other cell types such as glial, neu-
ronal, epithelial, and bone cells, where they have a crucial role in
mediating extracellular ATP signaling in release of cytokines (e.g.,
interleukin 1β) and proteases (e.g., cathepsins), neuron-glia inter-
actions, exocrine gland secretion, and bone remodeling (Jiang,
2012). There is also accumulating evidence to support a causative
role for altered expression and function of the mammalian P2X7Rs
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in a number of pathologies including arthritis, chronic pain, and
cancers (Donnelly-Roberts and Jarvis, 2007; Roger and Pelegrin,
2011; Adinolfi et al., 2012; Baroja-Mazo and Pelegrin, 2012; Di
Virgilio,2012; Jiang,2012). The past few years have witnessed enor-
mous high throughput screening efforts that have led to discovery
of a number of structurally diverse, selective, and potent P2X7R
antagonists; some of these molecules exhibit desirable drug-like
properties and therapeutically relevant efficacy in studies using
rodent disease models (Guile et al., 2009; Gum et al., 2012; Jiang,
2012). Natural compounds isolated from plants used in tradi-
tional medicines have also been shown to selectively inhibit the
P2X7Rs (Liu et al., 2010; Jelassi et al., 2013). Thus, the human
P2X7R has become a promising drug target. The recent clini-
cal trials of the first two P2X7R antagonists have however been
disappointing (Keystone et al., 2012; Stock et al., 2012), clearly
exposing the need for a better understanding of P2X7R-mediated
disease mechanisms. A clear delineation of the molecular deter-
minants for the functional properties of the mammalian P2X7Rs,
including the well-documented species differences that have seri-
ous implications for translation of preclinical animal studies into
clinical testing, is hugely desirable for development of small chem-
ical molecules targeting the human P2X7R as therapeutics. The
P2RX7 gene encoding the human P2X7R exhibits widespread sin-
gle nucleotide polymorphisms (SNPs), and among them there
are a large number of non-synonymous single nucleotide poly-
morphisms (NS-SNPs) that change the amino acid sequence and
result in a repertoire of human P2X7Rs with point mutations.
The gene for the mouse P2X7R (p2rx7 ) also contains NS-SNPs.
Recent efforts in characterization of such naturally occurring P2X7
mutant receptors have revealed, on one hand, previously unknown
molecular mechanisms for the mammalian P2X7R functions and,
on the other, an association of NS-SNPs with altered suscep-
tibility to various diseases. Studies of the NS-SNPs associated
with diseases have also shed new light on the underlying disease
mechanisms.
The review will provide an up-to-date overview of the
structure-function relationships of the mammalian P2X7Rs using
structural models based on the atomic structures of the zebrafish
P2X4.1Rs, and discuss the recent progress from studies of NS-
SNPs in understanding the molecular mechanisms that determine
the functional properties of the mammalian P2X7Rs and their
contributions in diseases.
AN OVERVIEW OF THE STRUCTURE-FUNCTION
RELATIONSHIPS
P2X7R PROTEINS
The P2X7Rs from six mammalian species (human, rhesus
macaque monkey, dog, rat, mouse, and guinea pig) and two non-
mammalian species (Xenopus and zebrafish) have thus far been
characterized in isolation to various extent (Surprenant et al., 1996;
Chessell et al., 1997; Rassendren et al., 1997a; Paukert et al., 2002;
Kucenas et al., 2003; Fonfria et al., 2008; Roman et al., 2009; Bradley
et al., 2011b). As shown in Figure 1, all the mammalian P2X7R
subunits comprise 595 amino acid residues except for the guinea
pig P2X7R subunit, which is one residue shorter due to omission
of Asp77 (in the human P2X7R numbering, used from this point
onward). The dog P2X7R subunit contains an asparagine residue
between positions 281 and 282 and lacks the residue correspond-
ing to Thr541 in the human P2X7R subunit. The Xenopus and
zebrafish P2X7R subunits contain 553 and 596 residues, respec-
tively. In a pair-wise comparison, the human P2X7R subunit shares
96% sequence identity with the monkey P2X7R subunit, 78–85%
with the other four mammalian P2X7R subunits, and 50–56%
with the Xenopus and zebrafish P2X7R subunits (Bradley et al.,
2011b).
All the P2XR subunits including those of P2X7Rs consist of
a large, glycosylated, and cysteine-rich extracellular domain, two
transmembrane domains (TM1 and TM2), a short intracellular
N-terminal domain and an intracellular C-terminal domain of
variable length (North, 2002; Kawate et al., 2009). The C-terminal
domain of the P2X7R subunits contains between 70 and 220 more
residues than that of the other P2XR subunits and thus is signifi-
cantly longer. The TM1 and TM2 domains in the human P2X7R
comprise residues Thr28-Ser47 and Asn332-Leu354, respectively
(shown in green in Figure 1).
THE STRUCTURAL MODELS OF HUMAN P2X7R
The structures in the closed and ATP-bound open states of the
zebrafish P2X4.1R in truncated forms consisting of the extracel-
lular and TM domains have been recently solved at 2.9 and 2.8 Å,
respectively (Hattori and Gouaux, 2012). The overall architecture
of the single subunit without the intracellular N- and C-terminal
domains has been imaginatively described to resemble the shape of
a dolphin leaping from the ocean (Figures 2A,B), with the extra-
cellular domain akin to the body and the TM domain to the tail
submerged in the water (Kawate et al., 2009; Hattori and Gouaux,
2012). The structure in the closed state contains eight α-helices
(α1–α8) and fourteen β-strands (β1–β14) connected by loops with
less defined structures (Figure 2A). In the open state, the α7 helix
is absent in the lower body domain and a short α-helix appears
in the head domain (Figure 2B). The multiple anti-parallel β-
strands in the upper and lower body domains form “connecting
rods” (Browne et al., 2010), which link the extracellular and TM
domains.
The extracellular and TM domains of the zebrafish P2X4.1R
and mammalian P2X7Rs show substantial sequence relatedness
(Figure 1), enabling structural models based on the former recep-
tor to provide meaningful insights into the molecular basis for the
functional properties of the latter receptors. Because of insertions
and deletions in the sequence relative to that of the zebrafish recep-
tor, the models of the human P2X7R subunit in the closed and
open states (Figures 2C,D) show several differences from the cor-
responding zebrafish P2X4.1R subunit structures (Figures 2A,B),
including the presence of a much longer loop connecting the β3
and β4 strands in the upper body domain and loss of the α4 helix
in the dorsal fin domain (Figures 2C,D).
The trimeric P2XR has a chalice-like shape (Kawate et al., 2009;
Hattori and Gouaux, 2012). In the structural models of the homo-
trimeric P2X7R in both the closed and open states, the three
subunits are positioned in a threefold symmetry around an axis
perpendicular to the plasma membrane and running through the
center of the receptor (Figure 3). The three extracellular domains
are tightly intertwined, making contacts at several points. The
TM domain is made of six helices, two from each of the three
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B2 SKKVGTLNRFTQALVIAYVIGYVFVYNKGYQDTDTVLSSVSTKVKGIALTKTS--ELG-----ERIWDVADYIIPPQEDGSFFVLTNMIITTNQTQSKC 119
C SKKVGTLNRFTQALVIAYVIGYVCVYNKGYQDTDTVLSSVSTKVKGIALTKTS--ELG-----ERIWDVADYIIPPQEDGSFFVLTNMIITTNQTQSKC 119
H MPACCSCSDVFQYETNKVTRIQSMNYGTI-KWFFHVIIFSYVCFALVSDKLYQRKEPVISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQG-NSFFVMTNFLKTEGQEQRLC 119
MM MPACCSCSDVFQYETTKVTRIQSMNYGTI-KWFFHVIVFSYVSFALVSDKLYQRKEPVISSVHTKVKGTAEVKEEIVENGVKKLVHSVFDTADYTFPLQG-NSFFVMTNFLKTEGQEQRLC 119
D MSACCSCNDIFQYETNKIIRIQSMNYGTI-KWIFHVIIFSYISFALISDKRYQQKEPLISSVHTKVKGTAEVKMEILENGIKKMVSTVFDTADYTFPLQG-NSFFVMTNFLKTEGQQQGFC 119 
R MPACCSWNDVFQYETNKVTRIQSVNYGTI-KWILHMTVFSYVSFALMSDKLYQRKEPLISSVHTKVKGVAEVTENVTEGGVTKLVHGIFDTADYTLPLQG-NSFFVMTNYLKSEGQEQKLC 119 
M MPACCSWNDVFQYETNKVTRIQSTNYGTV-KWVLHMIVFSYISFALVSDKLYQRKEPVISSVHTKVKGIAEVTENVTEGGVTKLGHSIFDTADYTFPLQG-NSFFVMTNYVKSEGQVQTLC 119 
GP MPGCSCWDDVFQYETNKVTRIQSRNYGTL-KWVLHLIVFSYISFALVTDKMYQRKEPVISSVHSKVKGMAEVTEEVV-GGVRRSVQKVLDTADYTLPLQG-NSFFVMTNYLQTEGQERGLC 118
L A   M                                     W
B2 AENPTPASTCTSHRDCKRGFNDARGDGVRTGRCVSYSASVKTCEVLSWCPLEKIVDPPNPPLLADAERFTVLIKNNIRYPKFNFNKRNILPNINSSYLTHCVFSRKTDPDCPIFRLGDIVG 240
C  AENPTPASTCTSHRDCKRGFNDARGDGVRTGRCVSYSASVKTCEVLSWCPLEKIVDPPNPPLLADAERFTVLIKNNIRYPKFNFNKRNILPNINSSYLTHCVFSRKTDPDCPIFRLGDIVG 240
H  PEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVHEGNQKTCEVSAWCPIEAVEEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNIT----CTFHKTQNPQCPIFRLGDIFR 236
MM PEYPTRRTLCSSDRGCKKGWMDPQSKGIQTGRCVVYEGNRKTCEVSAWCPIEAVGEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNIT----CTFHKTQNPQCPIFRLGDIFR 236
D  PEFPTRRTLCSNDWGCKKGWMDPQSKGIQTGRCIEYKGKQKTCEVSAWCPIEAVEEAPRPALLNGAENFTVLIKNNIDFPGHNYTTRNILPDINIT----CTFHKTQNPQCPIFRLGDIFQ 236
R  PEYPSRGKQCHSDQGCIKGWMDPQSKGIQTGRCIPYDQKRKTCEIFAWCPAEEGKEAPRPALLRSAENFTVLIKNNIDFPGHNYTTRNILPGMNIS----CTFHKTWNPQCPIFRLGDIFQ 236
M  PEYPRRGAQCSSDRRCKKGWMDPQSKGIQTGRCVPYDKTRKTCEVSAWCPTEEEKEAPRPALLRSAENFTVLIKNNIHFPGHNYTTRNILPTMNGS----CTFHKAWDPQCSIFRLGDIFQ 236
GP PEYPTPRTRCSSDRGCKKGWRDPKSKGIQTGRCVVYSGTTKTCEVAAWCPVEAVIEAPRPAILSSAENLTVLIKNNVHFPGHNYTTRNILPGLNAS----CTFHKTKNPECPIFRLGDIFQ 235
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B2 EAEEDFQIMAVRGGVMGVQIRWDCDLDMPQSWCVPRYTFRRLDNK-DPDNNVAPGYNFRFAKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNIIPTLLNIGAGLALLGLVNVICDWIV 360
C  EAEEDFQIMAVRGGVMGVQIRWDCDLDMPQSWCVPRYTFRRLDNK-DPDNNVAPGYNFRFAKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNIIPTLLNIGAGLALLGLVNVICDWIV 360
H  ETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCRPKYSFRRLDDK-TTNVSLYPGYNFRYAKYYK-ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLAAVFIDFLI 355
MM ETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCRPKYSFRRLDDK-TTNVSLYPGYNFRYAKYYK-ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLATVFIDFLI 355
D  QTGDNFSDVAIQGGIMGIEIHWDCNLDSWFHHCRPKYSFRRLDDKNTTTESLYPGYNFRYAKYYK-ENNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLATLFIDFLI 356 
R  EIGENFTEVAVQGGIMGIEIYWDCNLDSWSHRCQPKYSFRRLDDK-YTNESLFPGYNFRYAKYYK-ENGMEKRTLIKAFGVRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLATVCIDLII 355 
M  EAGENFTEVAVQGGIMGIEIYWDCNLDSWSHHCRPRYSFRRLDDK-NMDESFVPGYNFRYAKYYK-ENNVEKRTLIKAFGIRFDILVFGTGGKFDIIQLVVYIGSTLSYFGLATVCIDLLI 355 
GP EAGDNFSDVAVQGGIMGIEINWDCNLDKWSHHCRPKYSFRRLDDK-SVEEILVPGYNFRYAKYYR-ENNVEKRTLIKVFGVRFDILVFGTGGKFDIISLIVYIGSTLSYFGLATVFIDFLI 354 
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D  NTYSSKCCRSHIYPCFKCCEYCAVNEYYYKKKCETIVEPKPTLKYVSFVDEAHIRMVDQQLLRRRLQDVEGEEVPRPSMEFTDLSRLSLSLHDLSPIPGQSEEMQLLSEEVTPRSSNSPDW 477
R  NTYASTCCRSRVYPSCKCCEPCAVNEYYYRKKCEPIVEPKPTLKYVSFVDEPHIWMVDQQLLGKSLQDVKGQEVPRPQTDFLELSRLSLSLHHSPPIPGQPEEMQLLQIEAVPRSRDSPDW 476
M  NTYSSAFCRSGVYPYCKCCEPCTVNEYYYRKKCESIMEPKPTLKYVSFVDEPHIRMVDQQLLGKSLQVVKGQEVPRPQMDFSDLSRLSLSLHDSPLTPGQSEEIQLLHEEVAPKSGDSPSW 476
GP NTYSSALCRSHVYPWCPCCKPCAANEYYYRKKCQATVEPKPTLKYVSFVDEPHIRMVDQRLLGKSLQYVKGQKVPRPPTDFTLLSKLPTSPPDPAPAPTQLEEMQPLRRPDTSASGDSPEW 475
S P        R
H CQCGSCLPSQLPESHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDSTNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY 595
MM CQCGSCLPSQLPKSHRCLEELCCRKKPGACITTSELFRKLVLSRHVLQFLLLYQEPLLALDVDSTNSRLRHCAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKSEGQYSGFKSPY 595
D CQCGHCLPSQLPESQRCLEELCCRKKAGACITTSEPFRKLILSRQVLQFLLLYQEPLLVLDENS-NSRLRHCAYRCYTTWRFGSQDLADFAILPSCCRWRIRREFPKSEGQYSGFRSPY 595
R CQCGNCLPSQLPENRRALEELCCRRKPGQCITTSELFSKIVLSREALQLLLLYQEPLLALEGEAINSKLRHCAYRSYATWRFVSQDMADFAILPSCCRWKIRKEFPKTQGQYSGFKYPY 595
M CQCGNCLPSRLPEQRRALEELCCRRKPGRCITTSKLFHKLVLSRDTLQLLLLYQDPLLVLGEEATNSRLRHRAYRCYATWRFGSQDMADFAILPSCCRWRIRKEFPKTEGQYSGFKYPY 595
GP CQCGSCRPSQLPKDSRCLEELCCRRGPGPCITTSELFGDLVLSRPALRQLLLYQEPLLVLDGEATNSGLRHCAYRCYTTWRFGAQDVADFGILPSCCRWRIRSEFPRSHGQYSGFRCPY 594
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FIGURE 1 | Sequence comparison of the zebrafish P2X4.1R and
mammalian P2X7Rs. The amino acid sequences of the mammalian
P2X7Rs are aligned with the sequences of the truncated zebrafish
P2X4.1Rs with determined atomic structures (Hattori and Gouaux, 2012).
The ∆P2X4.1-B2 (B2) consisting of Ser28-Phe381 with changes at three
positions (C51F, N78K, and N187R) and the ∆P2X4.1-C (C) Ser28-Lys365
with changes at two positions (N78K and N187R) were used to determine
the structures in the closed (PDB accession number: 4DW0) and
ATP-bound open states (4DW1), respectively. The species abbreviations
are: H, human; MM, macaque monkey; D, dog; R, rat; M, mouse; GP,
guinea pig. The sequences in italics are absent in the atomic structures or
structural models. The same color scheme is used to indicate the different
domains in the human P2X7R sequence here and the dolphin-shaped
single subunit structural models shown in the following figures. The nine
residues in the mammalian P2X7Rs (10 in the zebrafish P2X4.1R, including
Leu217) involved in forming the inter-subunit ATP-binding site (shown in
Figure 3B) are highlighted with six residues from one subunit in pink and
another three residues from the complementary subunit in cyan (shown in
Figure 4). The residues in green are present in the structural regions
surrounding the ATP-binding site (also shown in Figure 4), changes of
which alter the agonist sensitivity or other functional properties of the
P2X7Rs (see text for details). The residues contributing to the
transmembrane ion-conducting pathway (shown in Figure 5B) and
residues in the extracellular lateral fenestrations are indicated in blue. The
underlined residues in the human and mouse P2X7Rs (shown in Figure 6)
are mutated by NS-SNPs to the residues shown underneath.
subunits; the three TM1 helices are located at the periphery, and
the three TM2 helices in the center and, when viewed parallel to
the plasma membrane, they all tilt at∼45˚ away from an axis per-
pendicular to the plasma membrane. Comparison of the closed
and open state structures indicates that the upper body domains
remain relatively static, whereas the other extracellular domains
of the protein such as the head and left flipper domains and the
TM domain undergo apparent conformational changes during
receptor activation (Figures 2B,D and 3).
THE CORE RESIDUES INVOLVED IN ATP-BINDING
Extracellular ATP is the only physiological agonist for the P2XRs,
but molecular cloning and sequence analyses indicate absence
of known ATP-binding consensus sequences. Detailed analysis of
the concentration-receptor ion channel activation curves and the
single channel activation kinetics suggests binding of three ATP
molecules to the mammalian P2XR or presence of three ATP-
binding sites (Bean, 1990; Ding and Sachs, 1999; Jiang et al., 2003).
It is worth mentioning that recent studies show that occupancy
of two of the three ATP-binding sites is sufficient for receptor
activation (Wilkinson et al., 2006; Stelmashenko et al., 2012).
Extensive site-directed mutagenesis and functional studies have
been conducted, leading to identification of a subset of conserved
hydrophilic residues in the extracellular domain that are key deter-
minants for activation of the mammalian P2XRs by ATP and struc-
turally related agonists (Evans, 2009, 2010; Browne et al., 2010).
Further investigations suggest that these residues are from two
neighboring subunits and that ATP binds at the subunit interface
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FIGURE 2 |The dolphin-like architectures of the zebrafish P2X4.1R and
human P2X7R subunits. (A,B) The structures of the zebrafish P2X4.1R
subunit in the closed (A) (PDB accession number: 4DW0) and ATP-bound
open states (B) (4DW1), respectively. (C,D) The structural models of the
human P2X7R subunit in the closed (C) and open states (D) generated
based on the structures of the zebrafish P2X4.1R (4DW0 and 4DW1,
respectively). The overall architecture of single P2XR subunit is analogous to
the shape of a leaping dolphin, with the extracellular and TM domains akin to
the body and the tail, respectively. The different domains are shown in
colors; tail in green, lower body in cyan, upper body in blue, head in purple,
dorsal fin in orange, right flipper in red, and left flipper in yellow (the same
color scheme as used in Figure 1). The five conserved disulfide bonds are
shown in white. The dotted circles (C) highlight the major differences in the
human P2X7R subunit compared with the zebrafish P2X4.1R subunit, and
the solid circles the major differences between the closed and open states
of the same receptors (B,D).
(Wilkinson et al., 2006; Marquez-Klaka et al., 2007, 2009). Despite
all the efforts, the structural basis for ATP-binding remained hypo-
thetical until the groundbreaking progress in solving the atomic
structure of the zebrafish P2X4.1R in complex with ATP (Hat-
tori and Gouaux, 2012). This ATP-bound structure reveals for the
first time the ATP-binding site of the P2XR, and nicely endorses
the ATP-binding features inferred from mutagenesis studies of the
mammalian P2XRs. The three ATP-binding pockets are readily vis-
ible at the three subunit interfaces (Figure 3B). The ATP-binding
site is situated at the apex of the ATP-binding pocket and consists of
10 residues from two adjacent subunits in the zebrafish P2X4.1R;
one subunit contributes four hydrophilic residues (Lys70, Lys72,
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FIGURE 3 |The chalice-like structural models of the human P2X7R. The
structural models of the trimeric human P2X7R in the closed (A) and
ATP-bound open state (B), based on the structures of the zebrafish P2X4.1R
(4DW0 and 4DW1, respectively), are viewed parallel to the plasma
membrane (top) or from the extracellular side of the membrane (bottom).
Each subunit is shown in a different color. Three ATP molecules shown in
space filling representation bind to the three inter-subunit interfaces. The
circle [top in (B)] shows one of the three lateral fenestrations for ions to
enter or exit from the transmembrane ion-conducting pathway in the open
state.
Thr189, and Lys193) and a further three hydrophobic residues
(Leu191, Leu217, and Ile232) while the complementary subunit
offers three hydrophilic residues (Asn296, Arg298, and Lys316)
(Hattori and Gouaux, 2012). The seven hydrophilic residues are
almost completely conserved in the mammalian P2XRs, and cor-
respond to Lys64, Lys66, Thr189, Lys193, Asn292, Arg294, and
Lys311 in the human P2X7R (Figure 1). They have been shown
to be critical in activation of the mammalian P2XRs including the
P2X7Rs (Worthington et al., 2002; Wilkinson et al., 2006; Adri-
ouch et al., 2008; Schwarz et al., 2009; Browne et al., 2010). The
three hydrophobic residues are found in some but not all the
mammalian P2X1R–P2X6R, the hydrophobicity, which is impor-
tant in interaction with ATP, is nevertheless highly preserved at
the equivalent three positions (Kawate et al., 2009). The mam-
malian P2X7Rs contain Leu191 and Ile228, equivalent to Leu191
and Ile232 in the zebrafish P2X4.1R, but apparently lack a residue
corresponding to Leu217 (Figure 1).
Figure 4 shows the ATP-binding site in the structural model of
the human P2X7R in the ATP-bound open state. ATP adopts a U -
shaped conformation. The triphosphate moiety and specifically
the β- and γ-phosphate groups are partially exposed. Lys64 in the
lower body in one subunit (referred to as subunit-B in Figure 4)
and particularly its side-chain NH+3 group is situated close to the
center of the triphosphate moiety, and forms hydrogen bonds with
all three phosphate groups. The side chains of Lys66 and Lys193,
also located in the lower body of the same subunit, interact with the
γ- and α-phosphate groups, respectively; the interaction of Lys193
with the α-phosphate group is predicted to be mediated by a water
molecule (not shown in Figure 4). The side chains of Asn292
and Lys311 and those of Arg294 and Lys311 in the upper body of
the complementary subunit (subunit-A in Figure 4) interact via
hydrogen bonds with the β- and γ-phosphate groups, respectively.
The adenine base forms hydrogen bonds with the side chain of
Thr189 and the main-chain carbonyl oxygen atoms of Lys66 and
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FIGURE 4 |The inter-subunit ATP-binding site in the human P2X7R.
Binding of ATP to the inter-subunit site in the human P2X7R in the open state
involves nine residues from two adjacent subunits. The subunit-B contributes
four hydrophilic residues (Lys64, Lys66, Thr187, and Lys197) and a further two
hydrophobic residues (Leu191 and Ile228) shown in magenta, and the
complementary subunit-A provides another three hydrophilic residues
(Gln292, Arg294, and Lys311) in cyan. The circle shows the approximate
boundary of the ATP-binding site. Changes of residues shown in green alter
the agonist sensitivity or ion channel gating of the mammalian P2X7Rs with
the exception of Arg125, which is the ADP-ribosylation site.
Thr189 in the lower body (subunit-B), and also makes hydropho-
bic interactions with Leu191 in the lower body and Ile228 in the
dorsal fin in the same subunit. A recent study has shown a criti-
cal role for Leu186 in the rat P2X2R, equivalent to Leu191 in the
human P2X7R, in recognizing the adenine base (Jiang et al., 2011).
Mutation of Leu191 to proline by NS-SNP in the human P2X7R
impaired the receptor function (Roger et al., 2010b). The hydroxyl
groups at positions 2′ and 3′ of the ribose ring face outwards, a
situation suggests that the ATP-binding site would readily tolerate
attachment of a bulky moiety to these positions. Consistent with
this hypothesis, BzATP acts as a potent agonist at all the P2XRs. As
mentioned above, a residue corresponding to Leu217 in the dorsal
fin domain of the zebrafish P2X4.1R, which in the latter specifi-
cally interacts with the ribose ring (Hattori and Gouaux, 2012), is
lacking in the mammalian P2X7Rs. It is thus tempting to specu-
late that loss of this residue or a difference in the local structure
of this region of the receptor is responsible for the low ATP sen-
sitivity and the higher potency of BzATP than ATP, the hallmark
pharmacological properties of the P2X7Rs. Interestingly, the cor-
responding region of the dorsal fin domain is variable in sequence
and length, and does contain a hydrophobic residue, Ile214 in the
human P2X7R (Figure 1). It remains unclear whether this residue
participates in the interaction with the ribose ring.
CONTRIBUTIONS FROM OTHER PARTS OR RESIDUES SURROUNDING
THE ATP-BINDING SITE
The structural models also give some insights into the roles of
parts or residues surrounding the ATP-binding site in determining
the functional properties of the mammalian P2X7Rs. Measure-
ments of BzATP-induced ionic currents showed that the charge-
neutralizing K145A mutation in the rat P2X7R reduced the BzATP
sensitivity (Liu et al., 2008). This residue is located in the head
domain, adjacent to the ATP-binding site (Figure 4). The pos-
itive charge of Lys145 is present in all the mammalian P2X7Rs
(Figure 1) and may facilitate agonist access or binding to the ATP-
binding site. In contrast, the charge-neutralizing R276A mutation
in the mouse P2X7R increased the sensitivity to ATP and BzATP, as
revealed by agonist-induced increases in the cytosolic Ca2+ level
and YO-PRO-1 uptake, and also slowed the open channel deac-
tivation (Adriouch et al., 2009). However, the charge-conserving
R276K mutation and, similarly the R277K mutation, enhanced
ATP-induced increases in the cytosolic Ca2+ level and YO-PRO-1
uptake without affecting the agonist sensitivity (Adriouch et al.,
2008, 2009). The NS-SNP R276H mutation increased (or H276R
reduced as described in the original study) ATP-induced ethid-
ium uptake (Stokes et al., 2010). This pair of positively charged
residues (R276 and R277 in the human P2X7R) is conserved in
the mammalian P2X7Rs (Figure 1) and also present in some other
P2XRs (Kawate et al., 2009). The structural models place them
in the lower body domain and away from the ATP-binding site
(Figure 4). The mutational effects together with their structural
location suggest that these two residues are likely involved in con-
formational changes accompanying ion channel gating or receptor
activation/deactivation.
The mammalian P2X7Rs exhibit striking differences in their
agonist sensitivity. Based on determination of the concentrations
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required to induce 50% of the maximal ionic currents (EC50),
the rat P2X7R exhibits 3∼ 10- and 30∼ 100-fold higher sensitiv-
ity to ATP, and BzATP, respectively, than the human (Rassendren
et al., 1997b; Bradley et al., 2011a) and mouse P2X7Rs (Young
et al., 2007). Substitution of Val154-Asn183 in the human P2X7R
with the corresponding segment from the rat P2X7R increased
the sensitivity to both ATP and BzATP (Michel et al., 2008).
Replacement of the entire extracellular domain (Ser47-Val334)
with that of the rat P2X7R caused the mouse P2X7R to show vir-
tually the same agonist sensitivity as the rat P2X7R, indicating that
the molecular determinants for the species difference in the ago-
nist sensitivity reside in the extracellular domain. The sensitivity
to ATP and BzATP of a mouse P2X7R, in which two small seg-
ments, Gln115-Ile136 and Tyr282-Phe288, were both substituted
by the corresponding ones of the rat P2X7R, was similar to that
of the rat P2X7R (Young et al., 2007). In the human P2X7R struc-
tural models, Glu115-Lys136 (corresponding to Gln115-Lys136
in the mouse P2X7R) and the N-terminal half (Val154-Cys168)
of Val154-Asn183 contribute to the head domain, the C-terminal
half (Pro169-Asn183) forms the loop connecting the head domain
and the α3 helix in the right flipper domain, and Thr282-Phe288
(equivalent to Tyr282-Phe288 in the mouse P2X7R) is in the
left flipper domain. These regions represent the key structural
components that embrace the ATP-binding site (Figure 4) and,
as discussed below, undergo significant conformational changes
during receptor activation. Characterization of the mouse P2X7R
carrying individual residues that are only present in the rat P2X7R,
has identified Asn284, and Lys127 in pair with Asn284, as critical
determinants for the higher sensitivity of the rat P2X7R to ATP and
BzATP, respectively (Young et al., 2007). Position 284 (occupied by
Asn284 in the human P2X7R; Figure 4) is situated at the tip of the
left flipper or the bottom half of the ATP-binding pocket; the neg-
ative charge of Asp284 in the mouse P2X7R may hinder agonist
access to the ATP-binding site, agonist-induced conformational
changes or both. Position 127 (occupied by Thr127 in the human
P2X7R) has been proposed to interact with BzATP (Young, 2010).
However, this residue is located on the outer edge of the top half
of the ATP-binding pocket and distant from the ATP-binding site
(Figure 4) and thus the positive charge of Lys127 in the rat P2X7R
is more likely to increase agonist accessibility to the ATP-binding
site and/or assist agonist-induced conformational changes.
The mouse P2X7R can be activated by extracellular nicoti-
namide adenine dinucleotide (NAD) independently of, or in
synergy with, ATP via ADP-ribosylation of the P2X7R protein cat-
alyzed by ADP-ribosyltransferase 2 ecto-enzymes (Seman et al.,
2003; Adriouch et al., 2008; Hong et al., 2009; Schwarz et al., 2012;
Xu et al., 2012). Arg125 in the extracellular domain has been iden-
tified by site-directed mutagenesis as the site for ADP-ribosylation
(Adriouch et al., 2008). ADP is known to poorly activate the
mammalian P2XRs including the mouse P2X7R (North and Sur-
prenant, 2000). The original study nonetheless hypothesized that
Arg125 is located in the close vicinity of the putative ATP-binding
site and ADP-ribosylation enables binding of the ADP or ADP-
ribose moiety to the ATP-binding site and thereby activation of
the receptor (Adriouch et al., 2008). The corresponding Arg125 in
the human P2X7R is in the head domain and indeed, as predicted,
projects toward the ATP-binding site from the tip of the top half of
the ATP-binding pocket (Figure 4), supporting the hypothesis that
ADP-ribose binds to the same site as ATP (Young, 2010). Arg276
is not an ADP-ribosylation site, but the R276K mutation signifi-
cantly increased the NAD sensitivity of the mouse P2X7R (Hong
et al., 2009; Schwarz et al., 2012). As discussed above, this residue is
located in the lower body domain and away from the ATP-binding
site (Figure 4) and thus the mutational effect on the NAD sensi-
tivity is likely to result from facilitation of conformational changes
leading to receptor activation.
Thus studies so far have provided clear evidence to support
the idea that the residues surrounding the ATP-binding site are
also important in determining the agonist sensitivity of the mam-
malian P2X7Rs, including the species differences in the agonist
sensitivity. Evidently, more studies are required to provide a better
and mechanistic understanding of their contributions. It is inter-
esting and also important to know whether the P2XR7-specific
regions or residues that surround the ATP-binding site are crucial
in determining the high potency and selectivity of P2X7R antago-
nists and particularly those of competitive antagonists (Jiang et al.,
2012).
THE SMALL CATION-CONDUCTING PATHWAY
Activation of the mammalian P2X7Rs opens, within milliseconds,
a transmembrane ion-conducting pathway selective for small
cations such as Ca2+, Na+, and K+. In the structural model of
the human P2X7R, the three TM2 helices, viewed from the cyto-
plasmic side of the plasma membrane, are seen to come into
close proximity at the approximate center of the bilayer, form-
ing a constriction, or physical gate that restricts ion flow in the
closed state (Figure 5A). Val335 and Ser342 (corresponding to
Leu340 and Ala347 in the zebrafish P2X4.1R) are located at the
extracellular and intracellular ends of the gate, respectively. In the
open state, Val335, Ser339, Ser342, Leu346, and Phe350 (equiva-
lent to Leu340, Ala344, Ala347, Leu351, and Ile355 in the zebrafish
P2X4.1R) represent the major structural components facing to the
ion-conducting pathway (Figure 5B). The narrowest part of the
open ion-conducting pathway in the zebrafish P2XR4.1 is defined
by three Ala347 residues with their Cα atoms being 6.4 Å from
the central axis (Hattori and Gouaux, 2012). The structural model
predicts a very similar size for the narrowest part of the open
ion-conducting pathway of the human P2X7R that is defined by
the corresponding Ser342 residues (Figure 5B). The same sub-
set of residues is expected to line the ion-conducting pathway
in the other mammalian P2X7Rs with the exception of Phe350,
which is replaced with cysteine in the rat and mouse P2X7Rs
(Figure 1). Introduction of the F350C mutation in the human
P2X7R however had no effect on the receptor function (Bradley
et al., 2011a). As discussed below, the A348T mutation by NS-
SNP in the human P2X7R, and the reciprocal T348A mutation
in the rat P2X7R, significantly altered the P2X7R ion channel
function. In the rat P2X7R, attachment of a positive charge at
position 348 by the T348K mutation, neutralization of the neg-
ative charge at Asp352 by the D352N mutation or replacement
with a positive-charge by the D352K mutation conferred a modest
Cl− permeability (Browne et al., 2013). Furthermore, mutation
of the equivalent residues in the rat P2X2R, Ser345 and Asp349,
changed single channel conductance (Cao et al., 2009). All these
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FIGURE 5 |The transmembrane ion-conducting pathway in the
human P2X7R. The arrangements of the transmembrane domains
(TM1s and TM2s) in the structural models of the human P2X7R in the
closed (A) and open states (B), viewed from the intracellular side of the
membrane. The three TM1 helices are located at the periphery and the
three TM2 helices in the center form the ion-conducting pathway.
Val335 and Ser342 represent the extracellular and intracellular ends of
the gate that restricts the ion flow in the closed state (A). Val335,
Ser339, Ser342, Leu346, Ala348, Phe350, and Asp352 form the
ion-conducting pathway in the open state (B). The circles in brown
illustrate the change in size of the ion-conducting pathway from the
closed to the open state.
mutagenesis studies consistently suggest that the residues at posi-
tions 348 and 352 in the mammalian P2X7Rs and at equivalent
positions in the other mammalian P2XRs are important parts of
the transmembrane ion-conducting pathway when the receptors
are in the open state.
The structure of the zebrafish P2X4.1R in the open state (Hat-
tori and Gouaux, 2012) and the analysis of cysteine accessibility in
the mammalian P2XRs (Kawate et al., 2011; Samways et al., 2011;
Jiang et al., 2012; Roberts et al., 2012) provide consistent evidence
in support of the notion that the three lateral fenestrations, located
just above the plasma membrane and linking to the extracellular
vestibule, act as the pathways for ions to enter or exit the aforemen-
tioned transmembrane ion-conducting pathway (Figure 3B). The
lateral fenestrations contain negatively charged residues, Asp59
and Asp61 in the zebrafish P2X4.1R (corresponding to Arg53 and
Glu55 in the human P2X7R; highlighted in blue in Figure 1).
However, charge-neutralization of the corresponding negatively
charged residues, Glu56, and Asp58, in the human P2X4R did
not alter the cation selectivity. Thus, the cation selectivity of the
P2XR ion channels has been attributed to the negative electrostatic
milieu of the extracellular vestibule (Samways et al., 2011; Hattori
and Gouaux, 2012). However, the contributing residues in the
mammalian P2XRs including the P2X7Rs remain to be identified.
THE ION CHANNEL GATING MECHANISM
The significant differences in the structures between the closed
and open states have given an unprecedented insight into the gen-
eral mechanism underlying ATP-induced gating of the P2XR ion
channels (Hattori and Gouaux, 2012). Occupation of the ATP-
binding site by extracellular ATP promotes lowering of the head
domain in one subunit and elevation of the dorsal fin domain in
the adjacent subunit to tighten the ATP-binding pocket and simul-
taneously causes a downward movement of the left flipper domain.
Such conformational changes induce outward movements of the
lower body domain or the “connecting rods” which in turn lead to
enlargement of the lateral fenestrations and extracellular vestibule
and to anticlockwise rotation of the TM helices around an axis per-
pendicular to the plasma membrane and their tilting away from an
axis parallel to the plasma membrane. The iris-like movements of
the TM helices cause the transition of the ion-conducting pathway
from the closed to the open state (Figure 5). Such a gating mecha-
nism is in principle supported by studies of the mammalian P2XRs
(Cao et al., 2007, 2009; Browne et al., 2010, 2013; Li et al., 2010;
Kawate et al., 2011; Jiang et al., 2012, 2013).
THE LARGE PORE AND ITS ENIGMATIC MECHANISM OF FORMATION
It has been known for decades that activation of the formerly
named P2Z receptor in immune cells (Cockcroft and Gomperts,
1979; Gordon, 1986), which was renamed the P2X7R after its mol-
ecular cloning (Surprenant et al., 1996), induces formation of a
large pore over tens of seconds to minutes. Similar formation
of large pores has been also described for the P2X2R, P2X4R,
P2X2/3R, and P2X2/5R (Khakh et al., 1999; Virginio et al., 1999b;
Compan et al., 2012). Two fundamentally different pore-forming
mechanisms were proposed more than 10 years ago (North, 2002),
but the evidence subsequently obtained has been conflicting and
difficult to reconcile with a single mechanism.
The first mechanism entails recruitment of a distinctive pore-
forming protein as a result of activation of the P2X7R. The
widely expressed pannexin-1 channel has attracted great attention,
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies May 2013 | Volume 4 | Article 55 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jiang et al. P2X7R function and disease mechanisms
because pharmacological inhibition using the channel inhibitor,
carbenoxolone, and the mimetic inhibitory peptide, 10Panx, or
selective knockdown of the pannexin-1 protein expression using
small interference RNA, strongly suppressed BzATP-induced YO-
PRO-1 uptake without effect on BzATP-induced ionic currents in
HEK293 cells heterologously expressing the rat P2X7R (Pelegrin
and Surprenant, 2006). These findings have recently been reca-
pitulated in peritoneal macrophage cells endogenously expressing
the mouse P2X7R (Sorge et al., 2012); both carbenoxolone and
10Panx prevented BzATP-induced YO-PRO-1 uptake but did not
alter BzATP-induced increases in the cytosolic Ca2+ level while,
by contrast, brilliant blue G, a P2X7R antagonist, inhibited both
BzATP-induced responses. Another recent study has reported that
BzATP-induced little YO-PRO-1 uptake in astrocytes isolated from
pannexin-1 transgenic knockout (KO) mice in contrast with the
robust dye uptake in astrocytes from wild-type mice (Suadi-
cani et al., 2012). These studies clearly support an indispensable
role for pannexin-1 in P2X7R-dependent pore formation. Treat-
ment of cells heterologously expressing the rat P2X7R or P2X2R
with colchicine to disrupt the microtubule cytoskeleton reduced
ATP-induced dye uptake without changing ATP-induced ionic
currents, and similar differential effects were seen in mouse peri-
toneal macrophages endogenously expressing the mouse P2X7R
(Marques-da-Silva et al., 2011). As discussed later, the NS-SNP
P451L mutation in the C-terminus of the mouse P2X7R can also
discriminate the two receptor functions in macrophage cells by
selectively impairing the large pore formation without effect on the
ion channel function. These observations are consistent with the
idea that the large dye uptake pore is different from the small ion-
permeable channel, although both depend on the P2XR activation
(Pelegrin, 2011). However, other studies strongly argue against the
role of pannexin-1; for example, there was no significant change in
ATP-induced YO-PRO-1 uptake in macrophage cells isolated from
another pannexin-1 KO mouse strain (Qu et al., 2011). Pharmaco-
logical inhibition of the pannexin-1 channel failed to alter the large
pore formation induced by activation of the P2X2R heterologously
expressed in HEK293 cells (Chaumont and Khakh, 2008) or the
P2X4R endogenously expressed in microglia (Bernier et al., 2012).
In the second mechanism, the large pore results from progres-
sive dilatation of the small ion-conducting pathway. The hypoth-
esis that the large pore represents an intrinsic functional property
of the P2X7R more readily explains the remarkable differences in
the large pore-forming capacity and dynamics upon activation of
P2X7Rs with a diversity of structural differences. Thus, the rat
P2X7R still functioned as a ligand-gated ion channel following
deletion of most of the C-terminal domain but failed to induce
YO-PRO-1 uptake (Surprenant et al., 1996). Similar functional
properties have been described for the human P2X7B alternative
splicing isoform, which has a very short C-terminal domain due
to replacement of the sequence comprising the last 249 residues
of the full-length protein (P2X7A) with an alternative 18 residue
sequence, whereas the heteromeric P2X7R formed by the P2X7A
and P2X7B subunits exhibits a greater capacity of forming the
larger pore than the homomeric P2X7A receptor (Adinolfi et al.,
2010). The mouse P2X7k alternative splicing isoform, with a dif-
ferent N-terminus and intracellular half of the TM1 helix, can
induce large pore formation with faster kinetics (Nicke et al., 2009;
Xu et al., 2012). In particular, substitution with tyrosine of the
highly conserved Gly345 residue in the rat P2X7R correspond-
ing to Gly350 in the zebrafish P2X4.1R, located in the TM2 helix
(Figure 1) and on the intracellular side of the gate (Figure 5),
caused complete loss of ATP-induced dye uptake without effect
on ATP-induced increases in the cytosolic Ca2+ level (Monif et al.,
2009). Mutations of the corresponding glycine residues in the
P2X2R (Gly342) and P2X4R (Gly347) (Khakh et al., 1999; Vir-
ginio et al., 1999b) or of residues in the C-terminal domain of the
P2X2Rs (Eickhorst et al., 2002) resulted in diverse and contrasting
effects on the large pore formation. A recent study has provided
compelling evidence to show that the rat P2X7R ion channel car-
rying G345C or T348C mutations was able to pass large molecules
with sizes up to 14 Å (Browne et al., 2013). The acid-sensing ion
channels (ASICs), despite exhibiting no significant sequence relat-
edness, have virtually the same membrane topology and subunit
stoichiometry as the P2XRs, and in fact, comparison of the atomic
structures of the chicken ASIC and zebrafish P2X4.1R indicates
a similar architecture of the ion-conducting pathways (Gonzales
et al., 2009; Browne et al., 2010). As revealed in a recent study,
the ASIC channel has two distinctive open states of the ion-
conducting pathway; one narrow open and Na+-selective state
at low extracellular pH, and one wide open and non-selective state
at high extracellular pH (Baconguis and Gouaux, 2012). Thus, it is
conceivable that agonist ligation of the P2XRs induces initial open-
ing of the small cation-conducting pathway which subsequently
expands and forms the large dye uptake pore.
In summary, the molecular basis for the large pore persistently
remains elusive. P2X7R-dependent large pore formation nonethe-
less acts as a signaling mechanism that plays a crucial role in
thymocyte cell death induced by ATP (Le Stunff et al., 2004) and
microglial activation and proliferation due to tonic receptor acti-
vation (Monif et al., 2009) and also, as have been shown in recent
studies, in a number of diseases, including chronic pain (Sorge
et al., 2012), pulmonary fibrosis (Riteau et al., 2010), inflam-
matory bowel diseases (Gulbransen et al., 2012), and osteoporsis
(Syberg et al., 2012). More studies are required to elucidate the
large pore-forming mechanisms as such information is obviously
necessary for a better understanding of the physiological and
pathophysiological roles of the mammalian P2X7Rs and identi-
fication of more specific intervention targets for development of
therapeutics.
NS-SNP INSIGHTS INTO MECHANISMS FOR P2X7R
FUNCTIONS AND DISEASES
IMPLICATIONS IN DISEASES
Non-synonymous SNPs in the P2RX7 gene have been identified
in patients with an increasing number and variety of conditions,
including chronic lymphocytic leukemia (CLL) (Thunberg et al.,
2002; Wiley et al., 2002; Starczynski et al., 2003; Zhang et al., 2003;
Dao-Ung et al., 2004; Nückel et al., 2004; Chong et al., 2010),
bipolar disorder (BP), major depressive disorder (MDD), and
anxiety disorders (Barden et al., 2006; Lucae et al., 2006; Erhardt
et al., 2007; Green et al., 2009; Grigoroiu-Serbanescu et al., 2009;
Hejjas et al., 2009; McQuillin et al., 2009), pulmonary tubercu-
losis (Franco-Martinez et al., 2006; Nino-Moreno et al., 2007),
osteoporosis in post-menopausal women (Ohlendorff et al., 2007;
www.frontiersin.org May 2013 | Volume 4 | Article 55 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jiang et al. P2X7R function and disease mechanisms
Gartland et al., 2012; Jørgensen et al., 2012) and fracture patients
(Husted et al., 2013; Wesselius et al., 2013), multiple sclerosis (MS)
(Oyanguren-Desez et al., 2011), systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA) (Portales-Cervantes et al.,
2012), ischemic stroke (IS) and ischemic heart disease (IHD) in
smokers (Gidlof et al., 2012), chronic inflammatory and neuro-
pathic pain (Sorge et al., 2012). More importantly, genetic linkage
studies have gathered evidence to support an association of NS-
SNPs with altered disease susceptibility, including A76V with MS
(Oyanguren-Desez et al., 2011); G150R with osteoporosis in frac-
ture patients (Husted et al., 2013; Wesselius et al., 2013); H155Y
and R270H with chronic inflammatory pain (Sorge et al., 2012);
R307Q with osteoporosis in post-menopausal women (Gartland
et al., 2012; Jørgensen et al., 2012); A348T with anxiety disor-
ders (Erhardt et al., 2007) and osteoporosis in post-menopausal
women (Jørgensen et al., 2012) and fracture patients (Husted et al.,
2013); R460Q with BP and MDD (Barden et al., 2006; Lucae
et al., 2006; Erhardt et al., 2007; Hejjas et al., 2009; McQuillin
et al., 2009; but, see Green et al., 2009; Grigoroiu-Serbanescu
et al., 2009) and osteoporosis in post-menopausal women (Jør-
gensen et al., 2012) and fracture patients (Husted et al., 2013;
Wesselius et al., 2013); E496A with CLL (Thunberg et al., 2002;
Wiley et al., 2002; but, see Starczynski et al., 2003; Zhang et al., 2003;
Nückel et al., 2004), tuberculosis (Nino-Moreno et al., 2007), IS,
IHD (Gidlof et al., 2012) and osteoporosis in post-menopausal
women (Ohlendorff et al., 2007; Jørgensen et al., 2012) and
fracture patients (Husted et al., 2013; Wesselius et al., 2013);
I568N with osteoporosis in post-menopausal women (Ohlen-
dorff et al., 2007; Jørgensen et al., 2012). The P451L NS-SNP
in the mouse p2rx7 gene is associated with neuropathic pain
(Sorge et al., 2012) and also with osteoporosis (Syberg et al.,
2012).
EFFECTS ON P2X7R FUNCTIONS
A small number of NS-SNP mutations in the human P2X7Rs have
been examined so far in terms of their effects on the ion channel
function, as measured by agonist-induced ionic currents, increases
in the cytosolic Ca2+ level or preloaded Rb+ efflux, and the large
pore function, as measured by agonist-evoked dye uptake. Agonist-
induced increases in the cytosolic Ca2+ level and dye uptake
in lymphocytes carrying the H155Y mutation were significantly
increased, indicating expression of a hyper-functional mutant
receptor (Cabrini et al., 2005; Portales-Cervantes et al., 2012). Sim-
ilarly, the A348T mutation increased (or reduced by the T348A
mutation described in the original study) agonist-induced dye
uptake (Denlinger et al., 2006). In contrast, agonist-induced dye
uptake levels in human lymphocyte, monocyte, and macrophage
cells carrying the T357S mutation were decreased, indicating that
the T357S mutant receptor was hypo-functional (Cabrini et al.,
2005; Shemon et al., 2006). Expression of the R307Q mutant
receptor in human monocyte, macrophage, lymphocyte, and nat-
ural killer (NK) cells resulted in complete loss of agonist-induced
Rb+ efflux and dye uptake (Gu et al., 2004). Agonist-induced dye
uptake was strongly impaired or completely lost in human mono-
cyte, macrophage, lymphocyte, and NK cells harboring the P2X7R
with the E496A or I568N mutations (Gu et al., 2001; Wiley et al.,
2002, 2003; Sluyter et al., 2004; Denlinger et al., 2005).
The above six and a further 12 more NS-SNP mutations in
the human P2X7R have been characterized in more detail upon
heterologous expression. Twelve of them are located in the extra-
cellular domain, including V76A, V80M, R117W, G150R, H155Y,
A166G, E186K, N187D, L191A, R270H, R276H, and R307Q
(Figures 1 and 6), which all significantly altered the receptor
function except for V80M. G150R, E186K, R276H, and R307Q
almost completely abolished, and V76A, R117W, N187D, R270H,
and L191P reduced, whereas H155Y and A166G (or A76V and
H270R reported in some studies) enhanced, agonist-evoked ionic
currents and/or dye uptake without altering the agonist sensitivity
except for N187D and possibly A166G (Gu et al., 2004; Cabrini
et al., 2005; Chong et al., 2010; Roger et al., 2010b; Stokes et al.,
2010; Sun et al., 2010; Bradley et al., 2011a; Oyanguren-Desez
et al., 2011). The N187D mutation increased the agonist EC50
value by threefold (Chong et al., 2010). The A348T mutation
in the TM2 helix (Figures 1 and 6) increased agonist-induced
ionic currents and dye uptake without altering the agonist sen-
sitivity (Cabrini et al., 2005; Roger et al., 2010b; Bradley et al.,
2011a). The other five NS-SNP mutations, T357S, Q460R, E496A,
H521Q, and I568N, are located in the cytoplasmic C-terminal
domain. The T357S mutation in the proximal part of this domain
reduced agonist-induced ionic currents and dye uptake without
altering the agonist sensitivity (Shemon et al., 2006; Roger et al.,
2010b). Both the Q460R and H521Q mutations had no effect on
agonist-induced ionic currents, increases in the cytosolic Ca2+
level, dye uptake, and agonist sensitivity (Cabrini et al., 2005;
Roger et al., 2010b). A very modest but significant reduction in
agonist-induced dye uptake by the Q460R mutation was reported
in another study (Stokes et al., 2010). The E496A mutation has
been subject to scrutiny by several groups. Two earlier indepen-
dent studies reported rather different effects on the ion channel
function; the E496A mutant and wild-type receptors mediated
similar agonist-induced ionic currents (Boldt et al., 2003) but
the mutant receptor-mediated agonist-induced Ca2+ influx was
largely lost (Cabrini et al., 2005). A subsequent study compar-
ing ATP-induced ionic currents and dye uptake under the same
experimental conditions showed that the E496A mutation strongly
impaired both the ion channel and dye uptake pore functions to
a similar degree without effect on the EC50 value for ATP (Roger
et al., 2010b). Expression of the I568N mutant receptor resulted
in no agonist-induced ionic current and dye uptake (Roger et al.,
2010b).
A few human P2X7R variants carry multiple NS-SNP muta-
tions (Stokes et al., 2010; Sun et al., 2010; Oyanguren-Desez et al.,
2011). For example, the P2X7R-2 variant contains H270R and
A348T mutations, and the P2X7R-4 variant has H155Y, H270R,
A348T, and Q460R mutations (Stokes et al., 2010). These variants
in human monocytes and erythrocytes mediated greater agonist-
induced Rb+ efflux and/or dye uptake. Consistently, these variants
in heterologous expression cells also exhibited larger agonist-
induced ionic currents and dye uptake with a similar agonist
sensitivity.
Characterizations of the NS-SNP mutations in the human
P2X7R have shed new light on previously unidentified molec-
ular determinants for the functions of the mammalian P2X7R
and other P2XRs. Among the 12 extracellular residues subject to
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies May 2013 | Volume 4 | Article 55 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jiang et al. P2X7R function and disease mechanisms
FIGURE 6 | Location of residues mutated by NS-SNPs in the extracellular
andTM domains. The residues in the extracellular and TM2 domains that are
mutated by NS-SNPs are shown in the structural models of the human P2X7R
subunit in the closed (A) and open states (B). The same color scheme is used
to indicate the different domains as in other figures. The residue at position
283 is mutated by NS-SNP in the mouse P2X7R.
NS-SNP mutation (Figure 1), Gly150 and Arg307 are completely
conserved and Gln187 is highly conserved in the mammalian
P2XR family (Kawate et al., 2009). Ala166, Glu186, Leu191, and
Arg276 are found in all mammalian P2X7Rs and also in some
other mammalian P2XRs (Kawate et al., 2009). The prominent
alterations in receptor functions by NS-SNP mutation of these
residues indicate that they are crucial for the mammalian P2XR
functions. Val76, Arg117, His155, and Arg270 are present in some
mammalian P2X7Rs including the human P2X7R (Figure 1). The
human P2X7R carrying the V76A, R117W, H155Y, or R270H
mutations exhibited significant changes in receptor functions, sug-
gesting that Val76, Arg117, His155, and Arg270 residues, albeit
less conserved, are also important for the P2X7Rs. Ala348 is only
present in the human P2X7R (Figure 1), and the A348T mutation
resulted in a hyper-functional receptor, supporting a functional
role for this residue. The hypo-functional phenotypes by NS-SNP
mutation of Thr357, Glu496, and Ile568 indicate the importance
of these residues in the C-terminal domain of all the mammalian
P2X7Rs (Figure 1).
So far four NS-SNP mutations in the mouse P2X7R have been
studied, including F11L in the N-terminus, A221T and M283T in
the extracellular domain, and P451L in the C-terminus (Figure 1)
(Adriouch et al., 2002; Le Stunff et al., 2004; Young et al., 2006,
2007). Phe11, Ala221, and Met283 are present in the mouse P2X7R
sequence encoded by the cDNA initially cloned from NTW8
microglial cells, whereas Leu11, Thr221, and Thr283 are found
in the P2X7R expressed in C57BL/6 and Balb/c mice (Young et al.,
2006). Both receptors exhibit a similar agonist sensitivity, but
agonist-induced ionic currents mediated by the receptor carry-
ing Leu11, Thr221, and Thr283 were ≥8-fold larger than those by
the receptor carrying Phe11, Ala221, and Met283 (Young et al.,
2006). Similarly, agonist-induced dye uptake was robust in cells
expressing the former receptor but was small or barely detectable
in cells expressing the latter receptor. Additional efforts of swap-
ping individual residues have identified the residue at position
283 as the key determinant (Young et al., 2006). The mouse
P2X7R ion channels carrying Pro451 or Leu451 exhibited the
same functional properties including agonist sensitivity, but the
P451L mutation strongly impaired or completely abolished the
ability of the receptor to induce large pore formation (Young
et al., 2006; Sorge et al., 2012; Xu et al., 2012), suggesting a pref-
erential role for the residue at position 451 in the pore-forming
process.
STRUCTURAL INSIGHTS INTO MOLECULAR MECHANISMS FOR THE
NS-SNP EFFECTS
It is known from the discussion above that Leu191 in the lower
body domain is one of the three hydrophobic residues in the
ATP-binding site and mediates hydrophobic interactions with the
adenine ring (Figures 4 and 6). Thus, the L191P mutation con-
ferred the hypo-functional phenotype most likely by impairing
the hydrophobic interactions with ATP as proposed in the original
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study (Roger et al., 2010b). Arg117, Gly150, His155, and Ala166
are all in the head domain, with Arg117 in the β5 strand, Gly150
immediately before the β6 strand, His155 in the loop between the
β6 and β7 strands, and Ala166 in the β7 strand (Figure 6). Glu186
and Gln187 are in the α3 helix of the right flipper domain, and
Arg270 and Arg276 are in the β12 strand leading toward the left
flipper domain (Figure 6). Thr283 in the human P2X7R (corre-
sponding to Met283 in the mouse P2X7R) is located in the left
flipper domain (Figure 6). These residues are within the above-
mentioned structural components surrounding the ATP-binding
site (Figure 4) and undergo conformational changes during recep-
tor activation. The NS-SNP mutations are likely to alter the local
structure and thereby the conformational changes. Finally, both
Val76 and Arg307 are located in the upper body domain, with
Val76 in the highly variable loop connecting the β3 and β4 strands
and Arg307 in the N-terminus of the β14 strand (Figure 6). The
upper body domain in the trimeric zebrafish P2X4.1R form“a rigid
scaffold” as they show little mobility during receptor activation
(Hattori and Gouaux, 2012). Interestingly, Arg312 in the structure
of the zebrafish P2X4.1R in both the closed and ATP-bound open
states, corresponding to Arg307 in the human P2X7R (Figure 1), is
involved in a network of hydrogen-bonding and salt-bridge inter-
actions with Gln114 in the β5 strand in the same chain and also
Asp88 and Asp91 in theα2 helix in the adjacent subunit (Figure 1).
These residues are highly conserved in the mammalian P2XRs
including the P2X7R, corresponding to Gln114, Asp89, and Asp92
in the human P2X7R. In silico mutation of Arg312 to glutamine or
to another positively charged lysine residue leads to apparent loss
of most of these interactions, and thus it is tempting to hypothesize
that disruption of such interactions may be responsible for the loss
of function associated with the R307Q NS-SNP mutation in the
human P2X7R (Roger et al., 2010b) and the R307K mutation in the
mouse P2X7R (Adriouch et al., 2008), and mutation of the corre-
sponding residues in other mammalian P2XRs (Jiang et al., 2000;
Browne et al., 2010; Evans, 2010). Ala348 is located in the TM2
helix (Figure 6) and, as discussed below, there is evidence suggest-
ing that the A348T mutation influences the ion channel gating and
large pore formation. Currently, there is no structural information
for the residues mutated by NS-SNPs in the C-terminus (Thr357,
Pro451, Glu496, and Ile568). It is worthwhile pointing out that
some of the NS-SNP mutations, such as I568N (Wiley et al., 2003)
and H155Y mutations as discussed below (Bradley et al., 2011a),
can mainly or additionally alter the expression of the receptor at
the cell surface.
MOLECULAR MECHANISMS DETERMINING SPECIES DIFFERENCES IN
RECEPTOR FUNCTIONS
H155Y and A348T are outstanding among all the NS-SNP muta-
tions identified so far in the human P2X7R, as they replace the
residues in the human P2X7R with the ones in the rat and other
mammalian P2X7Rs (Figure 1). Agonist-induced ionic current
and dye uptake mediated by the human P2X7R are significantly
smaller than those by the rat P2X7R (Rassendren et al., 1997b;
Bradley et al., 2011a). Both H155Y and A348T mutations gave
rise to hyper-functional receptors mediating increased agonist-
induced ionic currents and dye uptake, suggesting a role for the
residues at these two positions in determining the difference
in agonist-induced responses mediated by the human and rat
P2X7Rs. Consistently with this idea, introduction of the reciprocal
Y155H and T348A mutations in the rat P2X7R singly or together
resulted in the opposing effects by reducing agonist-induced ionic
currents (Bradley et al., 2011a). None of these mutations altered
the agonist sensitivity. The amplitude of agonist-induced ionic
currents is in principle governed by two distinctive mechanisms,
that is, the single channel properties (the single channel conduc-
tance and opening probability) and the surface expression (the
number of functional channels in the plasma membrane). To fur-
ther elaborate their role, His155 and Phe348 in the human P2X7R
were systematically replaced by residues bearing side chains dif-
fering in size, shape, or charge (Bradley et al., 2011a). All the
mutant receptors exhibited a similar ATP sensitivity. None of the
six substitutions introduced into the His155 position mimicked
H155Y, and the mutational effects exhibited no clear relationship
to the physiochemical properties of the side chain of the intro-
duced residues, indicating that Tyr155 is unique in conferring the
hyper-functional phenotype. In contrast, the effects of mutating
Ala348 were inversely correlated with the volume of the residues;
the residue with the smallest side chain conferred the greatest
increase in the amplitude of ATP-induced ionic currents, and the
ones with the larger side chains caused the greatest decrease, an
effect that is anticipated if the residue at this position is involved
in determining the single channel conductance and/or opening
probability (Bradley et al., 2011a). Consistently with this hypoth-
esis, recent studies, as discussed above, have presented compelling
evidence to show that the residue at this position in the rat P2X7R
and at the equivalent position in the rat P2X2R contributes to for-
mation of the transmembrane pathways permeating both small
ions and large organic molecules (Cao et al., 2009; Browne et al.,
2013). Immunofluorescent confocal imaging and biotin-labeling
assays have demonstrated that the H155Y mutation enhanced the
surface expression of the human P2X7R and, conversely, the reci-
procal Y155H mutation reduced the surface expression of the rat
P2X7R. Such complementary effects were not observed for the
A348T mutation in the human P2X7R and the T348A mutation
in the rat P2X7R, both of which had negligible effects on the sur-
face expression of the P2X7Rs (Bradley et al., 2011a). As already
described above, the residue at position 155 is located in the loop
connecting the β6 and β7 strands in the head domain, whereas
the residue at position 348 is present in the TM2 helix and on
the intracellular side of the ion channel gate (Figures 5 and 6).
The contrasting mutational effects on the ion channel function
and surface expression of the receptors are consistent with their
structural locations and together support the conclusion that the
residues at positions 155 and 348 contribute to the functional
difference between the human and rat P2X7Rs by modulating
the surface expression and single channel function, respectively
(Bradley et al., 2011a).
The M283T and P451L mutations rendered the mouse P2X7R
to be hyper-functional and hypo-functional, respectively. Thr283
and Pro451 are present in the human and other mammalian
P2X7Rs except for the guinea pig P2X7R in which Thr283 is
replaced by valine (Figure 1). Therefore, the residues at these two
positions may also contribute to the species difference between
the human and rodent P2X7Rs. Neither the M283T nor the P451L
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mutation altered the surface expression of the mouse P2X7R
(Young et al., 2006, 2007; Sorge et al., 2012). The residues at posi-
tion 283 is located in the left flipper domain that represents one
of the structural components surrounding the ATP-binding site
(Figure 4). Mutation of the residue at this position may fine-tune
the conformational changes accompanying receptor activation.
Position 451 is located in the middle of the cytoplasmic C-terminal
sequences (Figure 1), for which no structural information is avail-
able. As discussed above, the residue at this position is critical
for the ability to induce large pore formation but not for the
ion channel function of the P2X7Rs, the reason for this remains
elusive.
In summary, characterizations of the NS-SNPs in the human
and rodent P2X7Rs that swap species-specific residues have
revealed distinctive molecular mechanisms that determine the
functional differences in mammalian P2X7Rs.
P2X7R-MEDIATED MOLECULAR MECHANISMS IN DISEASES
The expression of the P2X7Rs in lymphocytes is well-documented.
CLL is a hematopoietic malignant tumor resulting from exces-
sive monoclonal expansion of B-lymphocytes and accumulation
of CD5+ lymphocytes in the blood. The basal or tonic level of the
P2X7Rs or activation at a low level is known to promote prolifer-
ation or growth of cells including lymphoid cells (Baricordi et al.,
1999; Adinolfi et al., 2005). Expression of the P2X7R was greater
in lymphocytes from CLL patients with the progressive variant
of the disease than in lymphocytes from patients with the indo-
lent or less severe variant, suggesting altered P2X7R expression
and function to contribute to the pathogenesis and progression
of CLL (Adinolfi et al., 2002). Strong stimulation of P2X7Rs can
induce cell death, garnering the reputation of a cytolytic recep-
tor (Surprenant et al., 1996; Virginio et al., 1999a). A recent study
has investigated the role in tumorigenesis of the N187D muta-
tion that was identified in human leukemic cells and resulted in a
hypo-functional receptor with reduced agonist sensitivity as dis-
cussed above (Chong et al., 2010). The mutation enhanced the
ability of the receptor to promote cell proliferation associated with
the basal receptor activity, and reduced the ability of the receptor
to mediate BzATP-evoked cell apoptosis. Relative to the tumors
induced by cells heterologously expressing the wild-type recep-
tor implanted in immune-deficient mice, the tumors induced by
cells expressing the mutant receptor grew faster, the size and weight
being larger and heavier, and the tumor tissues showed heightened
angiogenesis and macrophage infiltration. Such a detailed study
of the N187D NS-SNP mutation provides a new insight into how
altered P2X7R expression and function leads to hematopoietic
malignancies such as CLL.
Studies using transgenic KO mice and specific receptor antago-
nists have shown a critical role for the P2X7R in mediating chronic
neuropathic and inflammatory pain in rodent animals, but the
underlying receptor mechanisms remain less understood (Jiang,
2012). A recent study has reported that the mouse strains express-
ing the Pro451 allele encoding the wild-type receptor exhibited
more intense mechanical allodynia induced by nerve injury than
those expressing the Leu451 allele encoding the P451L mutant
receptor (Sorge et al., 2012). BzATP-induced similar increases
in the cytosolic Ca2+ level in macrophage cells from A/J mice
expressing the Pro451 allele and from B10.D2 mice express-
ing the Leu451 allele, but induced large pore formation only in
macrophage cells from the A/J mice. Furthermore, BzATP-induced
large pore formation in macrophage cells from the A/J mice was
strongly impaired following treatment with a peptide flanking
Pro451 (Ser445-Gln455) of the mouse P2X7R and fused to the
HIV-1 TAT domain (TAT-Pro451), but not with the TAT-peptide
containing Leu451 (TAT-Leu451). Neither of the TAT-peptides
altered BzATP-induced increases in the cytosolic Ca2+ level. Intra-
venous fusion of the TAT-P451 peptide into the A/J mice strongly
inhibited allodynia induced by nerve injury and inflammatory
allodynia induced by injecting complete Freund’s adjuvant in the
hind paws. The same study has also examined a cohort of patients
reporting chronic post-mastectomy pain; individuals carrying the
Tyr155 allele encoding the hyper-functional H155Y mutant recep-
tor suffered a higher level of pain compared to those with the
alleles encoding the wild-type receptor and, by contrast, individ-
uals with the His270 allele encoding the hypo-functional R270H
mutant receptor experienced a lower level of pain. In addition, the
R270H NS-SNP showed strong association with chronic inflam-
matory pain in a cohort of osteoarthritis patients. These findings
indicate P2X7R-dependent large pore-forming function is crit-
ical in determining the sensitivity to chronic neuropathic and
inflammatory pain.
P2X7 receptor is expressed in both osteoblasts and osteoclasts
and plays a crucial role in regulating bone remodeling (Ke et al.,
2003). As mentioned above, several NS-SNPs have been identified
in osteoporosis or fracture patients. Recent genetic linkage analyses
of separate cohorts of women with post-menopausal bone loss and
fractures (Ohlendorff et al., 2007; Gartland et al., 2012; Jørgensen
et al., 2012) and cohorts of fracture patients including both women
and men (Husted et al., 2013; Wesselius et al., 2013) have provided
consistent evidence to show significant association of NS-SNPs
with altered osteoporosis risk and fracture incidence. More specif-
ically, the NS-SNPs resulting in loss of functional mutations such
as G150R, R307Q, E496A, and I568N are associated with reduced
bone mineral density, increased bone loss, or high fracture inci-
dence while, by contrast, the NS-SNP mutation leading to gain of
function, A348T, is associated with increased bone mineral den-
sity and lower fracture incidence. Perhaps, the most informative
observations with respect to the role of P2X7R in the osteoporosis
disease mechanism have been provided by a recent study com-
paring the bone properties in mice expressing the P27R carrying
P451 or L451 residues (Syberg et al., 2012). The BALB/cJ and 129X
1/2J mice expressing the P451 P2X7R with a large pore-forming
ability displayed stronger femurs and higher expression level of C-
telopeptide collagen, a bone resorption marker, than C57Bl/6 and
DBA/2J mice expressing the L451 P2X7R defective in large pore
formation, suggesting that the large pore function is important in
regulating the resorption levels and bone remodeling.
In summary, genetic linkage studies and functional characteri-
zation of NS-SNP mutations have provided compelling evidence
to disclose P2X7R-dependent large pore formation as a previously
unrecognized molecular mechanism that underlies the sensitiv-
ity to chronic pain and the susceptibility to osteoporosis. Such a
mechanism may offer a more specific and promising therapeutic
target stratifying treatments of chronic pain and osteoporosis.
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CONCLUDING REMARKS
The mammalian P2X7Rs were identified at the molecular level
nearly two decades ago. Studies since then have accumulated a
large body of evidence to support an important role for the P2X7Rs
in mediating extracellular ATP signaling in health and disease. The
potential for developing therapeutics targeting the human P2X7R
remains high. As discussed in this review, the recent breakthroughs
in elucidating the atomic structures of the truncated zebrafish
P2X4.1R in the closed and ATP-bound open states have provided
the long-awaited structural information that is needed to gain
a better understanding of the molecular mechanisms underlying
ATP-binding, ion permeation, large pore formation, and activa-
tion of the mammalian P2X7Rs. Certainly one should bear in
mind that interpretations based on the current crystal structures
of the zebrafish P2X4.1R need to exercise cautions as the missing
cytosolic N- and C-terminal domains may significantly alter the
conformational changes and in particular the movements of the
transmembrane domains during receptor activation. No doubt,
the structures of a full-length mammalian P2X7R in the closed
and ATP-bound open states are required to provide a mechanis-
tic insight into the receptor functions, and particularly the role
of the P2X7R specific C-terminal domain (Costa-Junior et al.,
2011) and residues in this domain in receptor facilitation and
large pore formation (Jiang et al., 2005; Young et al., 2007; Roger
et al., 2008, 2010a; Sorge et al., 2012; Xu et al., 2012). The human
P2RX7 gene is highly rich in NS-SNPs, and characterizations of the
NS-SNP mutations identified in various disease conditions have
revealed additional molecular determinants for the human P2X7R
functions and, more importantly, have provided new insights into
disease mechanisms. It is anticipated that our increasing under-
standing of the structure-function relationships of the mammalian
P2X7Rs and of the P2X7R-mediated disease mechanisms will facil-
itate continuing efforts to exploit research on the bench for the
benefit of patients at the bedside.
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